While AI has revolutionised drug discovery and development in life sciences, its impact in commercialisation has been slower.

In Part 4 of our Life Sciences Industry Report, we turn our attention to advanced data analytics, wearable health devices, ...

As the race to deliver personalised engagement at scale gains pace, artificial intelligence (AI) has become a critical ...

A subsidiary of Sun Pharma has reached an agreement to buy the assets of Canada's Antibe Therapeutics, a developer of drugs ...

The US regulator has cleared Lumakras (sotorasib) in combination with Amgen's anti-EGFR antibody Vectibix (panitumumab) for ...

A trial exploring the use of a higher dose of Novo Nordisk's GLP-1 agonist semaglutide has shown that patients with obesity ...

Meanwhile, Sage reported failed phase 2 trials of dalzanemdor in Alzheimer's, Parkinson's, and Huntington's disease, and ...

At the top of that list, unsurprisingly, are Novo Nordisk obesity drugs Ozempic, Rybelsus, and Wegovy, all grouped together ...

Hospitals should expand and speed up testing of people hospitalised with influenza to see if they are suffering from bird flu ...

Generative artificial intelligence (GenAI) player Bioptimus has swelled its coffers with another financing round, raising $41 ...

Investor interest in companies with obesity candidates in their pipeline clearly remains high, given that a brand new ...

Each year at the JP Morgan Healthcare Conference, life sciences leaders congregate in San Francisco’s Union Square to network ...